Sangamo Therapeutics (SGMO) FCF Margin (2016 - 2025)
Historic FCF Margin for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to 4902.75%.
- Sangamo Therapeutics' FCF Margin fell 49266400.0% to 4902.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 239.2%, marking a year-over-year decrease of 147100.0%. This contributed to the annual value of 116.62% for FY2024, which is 229700.0% up from last year.
- As of Q3 2025, Sangamo Therapeutics' FCF Margin stood at 4902.75%, which was down 49266400.0% from 98.46% recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' FCF Margin registered a high of 23.89% during Q3 2024, and its lowest value of 10212.68% during Q1 2024.
- For the 5-year period, Sangamo Therapeutics' FCF Margin averaged around 1608.84%, with its median value being 231.61% (2021).
- In the last 5 years, Sangamo Therapeutics' FCF Margin tumbled by -101642500bps in 2024 and then soared by 98028200bps in 2025.
- Quarter analysis of 5 years shows Sangamo Therapeutics' FCF Margin stood at 226.26% in 2021, then decreased by -5bps to 236.96% in 2022, then crashed by -1000bps to 2605.73% in 2023, then skyrocketed by 98bps to 49.68% in 2024, then crashed by -9769bps to 4902.75% in 2025.
- Its last three reported values are 4902.75% in Q3 2025, 98.46% for Q2 2025, and 409.86% during Q1 2025.